NCT06218589
Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
Sponsored by Emory University
This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.
Inclusion Criteria: * Males and females age 2-20 years with suspicion of MASLD or presenting to liver clinic for evaluation of liver disease, including possible MASLD * For participants choosing to do MRI they have to be able to undergo MRI without sedation * Written/verbal informed consent from parent or legal guardian * Written/verbal informed assent from the child when indicated by age Exclusion Criteria: * Ascites * Pregnancy * Failure to give consent or assent * Have an implanted electronic device such as pacemaker, neurostimulator, or cochlear implant
Children's Healthcare of Atlanta (CHOA)
Atlanta, Georgia, United States
Emory Children's Center
Atlanta, Georgia, United States
Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.
Interested in this trial?
Express your interest and we'll connect you with the trial team.
Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.
Conditions